Inhalon Biopharma, Inc.
Monday, June 03, 2024
Respiratory
Company Presentation Theater 3
Inhalon Biopharma is a clinical-stage biotechnology company developing faster-acting, more effective, self-administered inhaled treatments to address the over $40B worldwide unmet need for patients suffering from acute respiratory infections (ARIs), including respiratory syncytial virus (RSV), influenza, HMPV and SARS-CoV-2.
Inhalon is using its patented drug delivery platform to revolutionize the treatment of viral respiratory infections. Inhalon’s breakthrough is a muco-trapping technology that directly binds to the virus and physically clears it. Virus trapping results in immediate reduction of viral load and prevents severe infection. Inhalon is the only company with broad issued patents covering inhaled treatment of ARIs with human monoclonal antibodies. Already, current partnerships with USAMRDC, NIH and Celltrion Healthcare have provided validation and funding to advance Inhalon’s proprietary platform.
Company Website:
https://www.inhalon.com/
Lead Product in Development:
IN-002 Inhaled Monoclonal Antibody for Respiratory Syncytial Virus (RSV)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 Unlicensed assets:
IN-003 for Inhaled Monoclonal Antibody for Human Metapneumovirus (preclinical)
IN-005 for Inhaled Monoclonal Antibody for Influenza (preclinical)
IN-006 Inhaled Monoclonal Antibody for SARS/ COVID 19 (Phase 2)
IN-007 Inhaled Monoclonal Antibody for Pan-SARS/ COVID 19 (preclinical)
Company HQ City
Morrisville
Company HQ State
North Carolina
Company HQ Country
United States
CEO/Top Company Official
John Whelan
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())